Imagine a company…
rethinking CNS
Doing Big
transforming the delivery of care
This is Sage

We are a clinical-stage biopharmaceutical company committed to discovering, developing and delivering novel medicines to transform the lives of patients with life-altering disorders of the central nervous system (CNS)

Learn More About Our Therapeutic Focus

News The latest from Sage

See All News

Press Releases

Sage Therapeutics Announces FDA Advisory Committee Votes 17-1 in Support of Benefit-Risk Profile of ZULRESSO™ (brexanolone) Injection for Treatment of Postpartum Depression

Events

Sage Q3 2018 Financial Results Conference Call (11/6/18)

In the news

See Sage CEO Jeff Jonas on CNBC’s Mad Money

Pipeline Advancing a robust CNS clinical portfolio

Learn More About Our Programs and Research

We seek to make a positive impact on the unmet treatment needs of patients by advancing product candidates from a robust development pipeline of potential CNS therapeutics.

Advancing a robust CNS clinical portfolio

Patients & Caregivers Putting patients and their families first

We are rethinking care and how it is delivered to help patients and families impacted by CNS disorders.

Postpartum Depression

Major Depressive Disorder

Patient Advocacy Programs
See Our Resources for Patients

Healthcare Providers It’s an exciting time in neuroscience

At Sage, our goal is to originate meaningfully differentiated drug candidates. We aim to transform the practice of medicine and rethink how CNS disorders are treated.

Learn More About Our Approach

Clinical Trials A distinct approach to neuroscience drug development

Sage is committed to developing new medicines to treat life-altering CNS disorders.

Learn More About Our Ongoing Clinical Trials

Working@Sage Rethinking CNS to make life better for patients and their families

Sage is a place where unconventional thinking to solve problems with new ideas is welcome - and where unconventional thinkers can imagine what's possible and do big.

Experience Our Culture